Veru Inc (VERU)

$2.11 -0.01 (-0.47%)
Market Cap 34.03M
Revenue (ttm) 0.00
Net Income (ttm) -22.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,100
Avg Vol 56,312
Day's Range N/A - N/A
Shares Out 16.05M
Stochastic %K 21%
Beta -1.19
Analysts Strong Sell
Price Target $24.50

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle l...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 509 6897
Address:
2916 North Miami Avenue, Suite 1000, Miami, United States
SuperGreenToday
SuperGreenToday May. 19 at 5:20 PM
$VERU Share Price: $2.08 Contract Selected: Jun 12, 2026 $2.0 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.28 – $0.35 Potential Upside: 58% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
maildriver
maildriver May. 18 at 6:39 PM
$VERU Management gets hundreds of thousands of shares for free and even selling them at $1 each is what keeps them going, not caring what the stock does
0 · Reply
WallStreetBuyDip
WallStreetBuyDip May. 18 at 12:58 AM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
fibonacci1170
fibonacci1170 May. 16 at 3:11 PM
$VERU 36-week interim analysis will be done and reported in Q1 2027. Assuming 31 March 2027 readout, and 1 month for data analysis, all 200 patients must be enrolled latest by 31 May 2026 to allow for 36-week treatment (Jun-Feb). The upside can be many multiples of the current mcap. Company is running on fumes, more dilution is expected, and phase 3 is a few years away... but I am keen on taking a starter position at the current all-time low of $2... preserving muscle mass and physical function in older adults is an untapped gold mine 🪙🪙🪙
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits May. 15 at 1:13 PM
$VERU another aggravated investor.
0 · Reply
mrkymrk
mrkymrk May. 14 at 8:01 PM
$VERU ouch. Steiner and this amazing management team keep getting all these worthless shares as compensation. Why don’t they actually do something to create shareholder value!!!
0 · Reply
EarningsInsider
EarningsInsider May. 13 at 1:02 PM
https://www.marketbeat.com/earnings/reports/2026-5-13-veru-inc-stock/ $VERU Veru Earnings Transcript
0 · Reply
mrkymrk
mrkymrk May. 13 at 12:36 PM
$VERU One question! And he didn’t even answer it! Will they need ONE or TWO phase 3 trials to gain approval?!? Not even addresses. Only rambling and mumbling. WTF.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 13 at 11:57 AM
$VERU Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.12 up 76.00% YoY
0 · Reply
Buyout_Imminent
Buyout_Imminent May. 12 at 7:45 PM
$VERU
0 · Reply
Latest News on VERU
Veru price target lowered to $24 from $25 at Oppenheimer

2026-05-15T14:08:45.000Z - 4 days ago

Veru price target lowered to $24 from $25 at Oppenheimer

Veru Inc. Earnings Call Transcript: Q2 2026

May 13, 2026, 8:00 AM EDT - 6 days ago

Veru Inc. Earnings Call Transcript: Q2 2026

Veru Inc. Earnings release: Q2 2026

May 13, 2026, 8:00 AM EDT - 6 days ago

Veru Inc. Earnings release: Q2 2026

Veru Inc. Quarterly report: Q2 2026

May 13, 2026, 8:00 AM EDT - 6 days ago

Veru Inc. Quarterly report: Q2 2026

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

May 13, 2026, 6:30 AM EDT - 6 days ago

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

May 6, 2026, 8:30 AM EDT - 13 days ago

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru files $200M mixed securities shelf

2026-04-07T20:25:46.000Z - 6 weeks ago

Veru files $200M mixed securities shelf

Veru files to sell 23.8M shares of common stock

2026-04-07T20:22:21.000Z - 6 weeks ago

Veru files to sell 23.8M shares of common stock

Veru Inc. Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 6 weeks ago

Veru Inc. Registration statement: Registration filing

Veru Inc. Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 6 weeks ago

Veru Inc. Registration statement: Registration filing

Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm

2026-03-09T12:35:23.000Z - 2 months ago

Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Mar 9, 2026, 8:30 AM EDT - 2 months ago

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 3:20 PM EST - 2 months ago

Veru Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Veru Inc. Slides: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 3:20 PM EST - 2 months ago

Veru Inc. Slides: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Veru Inc. Earnings Call Transcript: Q1 2026

Feb 11, 2026, 8:00 AM EST - 3 months ago

Veru Inc. Earnings Call Transcript: Q1 2026

Veru Inc. Quarterly report: Q1 2026

Feb 11, 2026, 8:00 AM EST - 3 months ago

Veru Inc. Quarterly report: Q1 2026

Veru Inc. Earnings release: Q1 2026

Feb 11, 2026, 8:00 AM EST - 3 months ago

Veru Inc. Earnings release: Q1 2026

Veru Inc. Quarterly report: Q1 2026

Feb 11, 2026, 8:00 AM EST - 3 months ago

Veru Inc. Quarterly report: Q1 2026

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Feb 4, 2026, 8:30 AM EST - 3 months ago

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2026, 7:00 AM EST - 3 months ago

Veru Inc. Proxy statement: Proxy Filing

Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2026, 7:00 AM EST - 3 months ago

Veru Inc. Proxy statement: Proxy Filing

Veru initiated with a Buy at Canaccord

2025-12-18T11:11:56.000Z - 5 months ago

Veru initiated with a Buy at Canaccord

Veru Inc. Earnings Call Transcript: Q4 2025

Dec 17, 2025, 8:00 AM EST - 5 months ago

Veru Inc. Earnings Call Transcript: Q4 2025

Veru Inc. Annual report: Q4 2025

Dec 17, 2025, 8:00 AM EST - 5 months ago

Veru Inc. Annual report: Q4 2025

Veru Inc. Earnings release: Q4 2025

Dec 17, 2025, 8:00 AM EST - 5 months ago

Veru Inc. Earnings release: Q4 2025

Options Volatility and Implied Earnings Moves Today, December 17, 2025

2025-12-17T12:05:23.000Z - 5 months ago

Options Volatility and Implied Earnings Moves Today, December 17, 2025

ABM EPAC GIS JBL MLKN MU TTC

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Dec 17, 2025, 6:30 AM EST - 5 months ago

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Dec 10, 2025, 8:30 AM EST - 5 months ago

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru Inc. Slides: Presentation

Nov 19, 2025, 5:24 PM EST - 6 months ago

Veru Inc. Slides: Presentation

Veru to Present Two Abstracts at ObesityWeek 2025

Oct 31, 2025, 8:30 AM EDT - 7 months ago

Veru to Present Two Abstracts at ObesityWeek 2025

Veru prices 1.4M shares at $3.00 in underwritten public offering

2025-10-30T12:31:52.000Z - 7 months ago

Veru prices 1.4M shares at $3.00 in underwritten public offering

Veru announces pricing of $25M public offering

2025-10-30T12:26:38.000Z - 7 months ago

Veru announces pricing of $25M public offering

Veru announces offering of common stock and warrants, no amount given

2025-10-29T20:14:01.000Z - 7 months ago

Veru announces offering of common stock and warrants, no amount given

Veru Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 7 months ago

Veru Announces Proposed Public Offering

Veru announces FDA meeting providing regulatory clarity for Enobosarm

2025-09-23T12:35:59.000Z - 8 months ago

Veru announces FDA meeting providing regulatory clarity for Enobosarm

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Sep 23, 2025, 8:30 AM EDT - 8 months ago

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Veru Inc. Earnings Call Transcript: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Veru Inc. Earnings Call Transcript: Q3 2025

Veru Inc. Quarterly report: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Veru Inc. Quarterly report: Q3 2025

Veru Inc. Earnings release: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Veru Inc. Earnings release: Q3 2025

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Aug 12, 2025, 6:30 AM EDT - 10 months ago

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru announces selection of modified release of enobosarm for PK study

2025-08-11T12:35:24.000Z - 10 months ago

Veru announces selection of modified release of enobosarm for PK study

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Aug 11, 2025, 8:30 AM EDT - 10 months ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru trading halted, news pending

2025-08-08T23:50:15.000Z - 10 months ago

Veru trading halted, news pending

Veru announces 1-for-10 reverse stock split

2025-08-06T12:36:18.000Z - 10 months ago

Veru announces 1-for-10 reverse stock split

Veru Announces Reverse Stock Split

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Veru Announces Reverse Stock Split

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Jul 22, 2025, 8:30 AM EDT - 10 months ago

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Veru Inc. Proxy statement: Proxy Filing

Jul 15, 2025, 8:00 AM EDT - 11 months ago

Veru Inc. Proxy statement: Proxy Filing

Veru to Participate in the Virtual BTIG Obesity Health Forum

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

Veru Inc. Proxy statement: Proxy Filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Veru Inc. Proxy statement: Proxy Filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 28, 2025, 6:30 AM EDT - 1 year ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

Veru Inc. Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:30 AM EDT - 1 year ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 9:25 AM EDT - 1 year ago

Veru Participates in a Virtual Investor KOL Connect Segment

Veru Inc. Earnings Call Transcript: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings Call Transcript: Q2 2025

Veru Inc. Quarterly report: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Quarterly report: Q2 2025

Veru Inc. Earnings release: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings release: Q2 2025

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 8, 2025, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

May 1, 2025, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Veru Inc. Earnings Call Transcript: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Earnings Call Transcript: Q1 2025

Veru Inc. Quarterly report: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Quarterly report: Q1 2025

Veru Inc. Earnings release: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Earnings release: Q1 2025

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Feb 13, 2025, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru Inc. Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 12:00 PM EST - 1 year ago

Veru Inc. Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Veru Inc. Proxy statement: Proxy Filing

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Jan 27, 2025, 6:30 AM EST - 1 year ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Veru Inc. Transcript: Study Result

Jan 26, 2025, 7:00 PM EST - 1 year ago

Veru Inc. Transcript: Study Result

Veru Inc. Press release: Study Result

Jan 26, 2025, 7:00 PM EST - 1 year ago

Veru Inc. Press release: Study Result

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Dec 31, 2024, 8:30 AM EST - 1 year ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru Inc. Annual report: Q4 2024

Dec 16, 2024, 12:00 AM EST - 1 year ago

Veru Inc. Annual report: Q4 2024

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 26, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Nov 5, 2024, 8:30 AM EST - 1 year ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Veru Inc. Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 1:55 PM EDT - 1 year ago

Veru Inc. Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Veru to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Veru Inc. Earnings Call Transcript: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings Call Transcript: Q3 2024

Veru Inc. Quarterly report: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Veru Inc. Quarterly report: Q3 2024

Veru Inc. Earnings release: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings release: Q3 2024

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jul 2, 2024, 8:30 AM EDT - 2 years ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. Proxy statement: Proxy Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 18, 2024, 4:05 PM EDT - 2 years ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Veru Inc. Proxy statement: Proxy Filing

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 17, 2024, 4:45 PM EDT - 2 years ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 11:00 AM EDT - 2 years ago

Veru Inc. Transcript: Jefferies Global Healthcare Conference

Veru to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the Jefferies Global Healthcare Conference

Veru Announces Steven B. Heymsfield M.D.

May 15, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Steven B. Heymsfield M.D.

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 14, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

Veru Inc. Proxy statement: Proxy Filing

May 9, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Veru Inc. Proxy statement: Proxy Filing

May 9, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Veru Inc. Earnings Call Transcript: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings Call Transcript: Q2 2024

Veru Inc. Quarterly report: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Quarterly report: Q2 2024

Veru Inc. Earnings release: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings release: Q2 2024

Veru Inc. Slides: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Slides: Q2 2024

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 8, 2024, 6:30 AM EDT - 2 years ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

Veru to Present at the GLP-1 Based Therapeutics Summit

May 2, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the GLP-1 Based Therapeutics Summit

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Veru Inc. Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Veru Reschedules Annual Meeting of Shareholders

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Veru Reschedules Annual Meeting of Shareholders

Veru Inc. Proxy statement: Proxy Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 27, 2024, 7:15 PM EST - 2 years ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 20, 2024, 8:30 AM EST - 2 years ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

SuperGreenToday
SuperGreenToday May. 19 at 5:20 PM
$VERU Share Price: $2.08 Contract Selected: Jun 12, 2026 $2.0 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.28 – $0.35 Potential Upside: 58% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
maildriver
maildriver May. 18 at 6:39 PM
$VERU Management gets hundreds of thousands of shares for free and even selling them at $1 each is what keeps them going, not caring what the stock does
0 · Reply
WallStreetBuyDip
WallStreetBuyDip May. 18 at 12:58 AM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
fibonacci1170
fibonacci1170 May. 16 at 3:11 PM
$VERU 36-week interim analysis will be done and reported in Q1 2027. Assuming 31 March 2027 readout, and 1 month for data analysis, all 200 patients must be enrolled latest by 31 May 2026 to allow for 36-week treatment (Jun-Feb). The upside can be many multiples of the current mcap. Company is running on fumes, more dilution is expected, and phase 3 is a few years away... but I am keen on taking a starter position at the current all-time low of $2... preserving muscle mass and physical function in older adults is an untapped gold mine 🪙🪙🪙
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits May. 15 at 1:13 PM
$VERU another aggravated investor.
0 · Reply
mrkymrk
mrkymrk May. 14 at 8:01 PM
$VERU ouch. Steiner and this amazing management team keep getting all these worthless shares as compensation. Why don’t they actually do something to create shareholder value!!!
0 · Reply
EarningsInsider
EarningsInsider May. 13 at 1:02 PM
https://www.marketbeat.com/earnings/reports/2026-5-13-veru-inc-stock/ $VERU Veru Earnings Transcript
0 · Reply
mrkymrk
mrkymrk May. 13 at 12:36 PM
$VERU One question! And he didn’t even answer it! Will they need ONE or TWO phase 3 trials to gain approval?!? Not even addresses. Only rambling and mumbling. WTF.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 13 at 11:57 AM
$VERU Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.12 up 76.00% YoY
0 · Reply
Buyout_Imminent
Buyout_Imminent May. 12 at 7:45 PM
$VERU
0 · Reply
GenralZod
GenralZod May. 12 at 4:01 PM
$VERU as cash dwindles so will this price. whats the bottom? enobosarm approval some year, maybe? probably not. idk. But, I will play along that it will get some hype and the ticker will run. $200M cap? $500M cap? I've seen it before and Mitch can pump the fast ball. I offer him cigar and rum. He will come
2 · Reply
mrkymrk
mrkymrk May. 12 at 2:00 PM
$VERU how much is Rambling Mitch going to tank the stock tomorrow?? He only has $35 M in market cap left to destroy
0 · Reply
WallStreetBuyDip
WallStreetBuyDip May. 5 at 3:16 PM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 30 at 1:31 AM
$VERU Current Stock Price: $2.22 Contracts to trade: $1.5 VERU May 01 2026 Call Entry: $0.60 Exit: $1.19 ROI: 98% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Johnspeed
Johnspeed Apr. 28 at 12:14 PM
$VERU how Mitch is driving this company
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 22 at 8:58 AM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 10 at 5:56 PM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 9 at 8:35 PM
$VERU RSI: 58.33, MACD: -0.0036 Vol: 0.11, MA20: 2.32, MA50: 2.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
mrkymrk
mrkymrk Apr. 8 at 11:29 AM
$VERU ‘@BioRich I reading this right… that investors in VERU just exercised their warrants with at $3.00 strike price when the stock is only trading at $2.50?
1 · Reply
BioRich
BioRich Apr. 1 at 3:03 PM
$CYCN Congrats on the great merger news today. Long road but hopefully people still made a premium. Cheers! $VERU $LPCN $CYCN $ALUR $NRSN
0 · Reply
triniblockchain
triniblockchain Apr. 1 at 12:32 AM
$VERU any chance this recovers from the dead?
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits Mar. 27 at 9:04 AM
$VERU The bogosity that rears here is the protracted timeline. End of 2027 for the phase 2? Sad.
0 · Reply